The Swiss drugmaker company, Rocher has manufactured a drug-Perjeta, which can be used to treat advanced states of breast cancer. This has appeared as an unparalleled success in prolonging lives, researchers reported as indicated in a clinical trial. As per the consequences of the trial, the patients receiving this drug had a median survival time nearly 16 months more than those lacking it. According to the researchers, 16 months is the longest time period in which a drug is used as an initial treatment of metastatic breast cancer. Perhaps this may be the longest time required to treat cancer also.
“The survival improvement of nearly 16 months…is unprecedented among studies of metastatic breast cancer”, lead researcher Sandra Swain from the Washington Hospital Center told the European Society for Medical Oncology annual congress on Sunday.